Description
The family of Bromodomain and Extra Terminal domain (BET) proteins are capable of binding to acetylated histone lysine residues to control DNA transcription. The BET proteins have two binding sites capable of recognizing acetylated lysine, sites 1 and 2. Researchers at St. Jude have discovered potent small molecule inhibitors that not only discriminate between BET family members, but can selectively prevent the binding of acetylated lysine to one binding domain in the presence of the other. The researchers propose that selective inhibition will lead to unique biological outcomes that current state of the art non-selective compounds will not.
These current pan-BET inhibitors (which block both BET binding domains with equal potency) have been linked to sterility and loss of cognitive function in mouse studies, likely due to the inability to discriminate between BET binding domains and family isoforms which control spermatogenesis. The new compounds selectively inhibit the second binding domain more strongly than the first binding domain in BET isoforms BRD2 and BRD4. They are also able to discriminate between family isoforms as well being less potent against BRD-T. This selectivity will lead to better outcomes when these compounds are administered, through higher potency, better tolerability, and fewer side effects than start of the art compounds.
We are seeking a partner who will license and help develop these inhibitors. At a minimum, these small molecules will benefit the research community by probing the effect of selective BET inhibition in biological contexts; and they also have the potential to be developed into novel pharmaceutical therapies for the treatment of cancer and inflammatory diseases.
Keywords
Bromodomain and Extra Terminal domain (BET) proteins, DNA transcription, acetylated lysine, small molecule inhibitors, cancer and inflammatory diseases.
Granted Patents or Published Applications
Related Scientific References
Licensing Opportunities
Please contact us if you are interested in licensing this technology. Contact: chad.riggs@stjude.org
Related Links
Technologies
- Biologically Active Ganoderma Lucidum Compounds and Synthesis of Derivatives and Probes (SJ-19-0035)
- Compounds for Treatment of BCR-ABL + Lymphoblastic Leukemias (using an existing malaria drug to overcome resistance) (SJ-11-0042)
- DON and small molecule Bcl-2 family antagonists treating glutamine addicted cell lines for Neuroblastomas and Ewing sarcomas (SJ-13-0026)
- EZHIP(CXorf67)-PRC2 Interaction and Ependymoma (SJ-17-0030)
- Hybrid Compounds to treat Gastrointestinal Infections (SJ-14-0019/UTA 14-01)
- Improved Human Carboxylesterase for Therapy with CPT-11 (SJ-06-0006)
- Method for Improving Learning and Treating Neurological Diseases (SJ-15-0009)
- Method for treating COVID-19 (SJ-20-0035)
- Methods and compositions for the prevention and treatment of hearing loss using CDK2 inhibitors (SJ-14-0028)
- Methods for Diagnosing and Treating Learning or Mental Disorders with the SERCA2 Protein and miRNAs that regulate SERCA2 Levels (SJ-10-0003 and SJ-12-0020)
- New Uses for Chloroquine and Chloroquine Analogs (SJ-02-0008 and SJ-05-0017)
- Novel Carboxylesterase Inhibitors (SJ-02-0030)
- P27 Inhibitors for Hearing Regeneration and/or Breast Cancer (SJ-18-0016)
- SARM for Kennedy's Disease (SJ-18-0012)
- SPA70 is a potent antagonist of human pregnane X receptor (PXR Antagonists) (SJ-16-0011)
- Sudemycins: Synthetic Natural Product Analogs as Anti-Cancer Agents (SJ-08-0026 & SJ-13-0007)
- Thalamic microRNA controls the late onset of schizophrenia (SJ-15-0035)
- Therapeutic Leads Targeting Influenza Endonuclease (SJ-09-0041)
- Transcription Factors for Cochlear Hearing Loss Therapy (SJ-17-0016)
- Treating Cochlear Hearing loss with p27Kip1/Atoh1 Combinations (SJ-13-0019)
- Use of metabolic drugs to treat influenza infection (SJ-14-0040)
- Use of specific retinoid receptor agonists and antagonists as cancer therapies (SJ-14-0011)
- Use of Ulk1 modulators to treat thalassemia (SJ-18-0004)
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.